Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 148


A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.

Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E.

Oncology. 2019;97(2):102-111. doi: 10.1159/000500571. Epub 2019 Jun 21.


Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation.

Zumsteg ZS, Luu M, Kim S, Tighiouart M, Mita A, Scher KS, Lu DJ, Shiao SL, Mallen-St Clair J, Ho AS.

Ann Oncol. 2019 Jun 5. pii: mdz172. doi: 10.1093/annonc/mdz172. [Epub ahead of print] No abstract available.


Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.

Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, Awad M, Calvo E, Moreno V, Govindan R, Spira A, Gonzalez M, Zhong B, Santiago-Walker A, Poggesi I, Parekh T, Xie H, Infante J, Tabernero J.

Clin Cancer Res. 2019 Aug 15;25(16):4888-4897. doi: 10.1158/1078-0432.CCR-18-3334. Epub 2019 May 14.


Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.

Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H.

J Immunother Cancer. 2019 Feb 4;7(1):30. doi: 10.1186/s40425-019-0508-1.


Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.

Ou Y, Xu Y, Gore L, Harvey RD, Mita A, Papadopoulos KP, Wang Z, Cutler RE Jr, Pinchasik DE, Tsimberidou AM.

Br J Clin Pharmacol. 2019 Mar;85(3):530-539. doi: 10.1111/bcp.13817. Epub 2018 Dec 25.


Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation.

Zumsteg ZS, Luu M, Kim S, Tighiouart M, Mita A, Scher KS, Lu DP, Shiao SL, Mallen-St Clair J, Ho AS.

Ann Oncol. 2019 Jan 1;30(1):76-84. doi: 10.1093/annonc/mdy490.


Human papillomavirus-associated oropharyngeal cancer among patients aged 70 and older: Dramatically increased prevalence and clinical implications.

Lu DJ, Luu M, Mita A, Scher K, Shiao SL, Yoshida EP, Sittig MP, Mallen-St Clair J, Ho AS, Zumsteg ZS.

Eur J Cancer. 2018 Nov;103:195-204. doi: 10.1016/j.ejca.2018.08.015. Epub 2018 Sep 27.


Quantitative survival impact of composite treatment delays in head and neck cancer.

Ho AS, Kim S, Tighiouart M, Mita A, Scher KS, Epstein JB, Laury A, Prasad R, Ali N, Patio C, Clair JM, Zumsteg ZS.

Cancer. 2018 Aug 1;124(15):3154-3162. doi: 10.1002/cncr.31533. Epub 2018 May 9.


Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.

Abumiya M, Mita A, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M.

Med Oncol. 2018 May 7;35(6):90. doi: 10.1007/s12032-018-1146-z.


Divergent antioxidant capacity of human islet cell subsets: A potential cause of beta-cell vulnerability in diabetes and islet transplantation.

Miki A, Ricordi C, Sakuma Y, Yamamoto T, Misawa R, Mita A, Molano RD, Vaziri ND, Pileggi A, Ichii H.

PLoS One. 2018 May 3;13(5):e0196570. doi: 10.1371/journal.pone.0196570. eCollection 2018.


Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia.

Mita A, Abumiya M, Miura M, Niioka T, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N.

Exp Hematol Oncol. 2018 Apr 13;7:9. doi: 10.1186/s40164-018-0101-1. eCollection 2018.


Rorschach Evaluation of Personality and Emotional Characteristics in Adolescents With Migraine Versus Epilepsy and Controls.

Balottin L, Mannarini S, Candeloro D, Mita A, Chiappedi M, Balottin U.

Front Neurol. 2018 Mar 20;9:160. doi: 10.3389/fneur.2018.00160. eCollection 2018.


Perspectives in Head and Neck Medical Oncology.

Amanam I, Gupta R, Mita A, Scher K, Massarelli E.

Cancer Treat Res. 2018;174:163-185. doi: 10.1007/978-3-319-65421-8_10.


Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification.

Yoshida EJ, Luu M, David JM, Kim S, Mita A, Scher K, Shiao SL, Tighiouart M, Ho AS, Zumsteg ZS.

Head Neck. 2018 Jun;40(6):1228-1236. doi: 10.1002/hed.25100. Epub 2018 Feb 8.


LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.

Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, Kurth I, Andreu-Agullo C, Derbyshire ML, Posada J, Takeda S, Tafreshian KN, Rowinsky E, Szarek M, Waltzman RJ, Mcmillan EA, Zhao C, Mita M, Mita A, Chmielowski B, Postow MA, Ribas A, Mucida D, Tavazoie SF.

Cell. 2018 Feb 8;172(4):825-840.e18. doi: 10.1016/j.cell.2017.12.026. Epub 2018 Jan 11.


Difficulty in positive diagnosis of ascites and in differential diagnosis of a pulmonary tumor.

ForŢofoiu MC, Popescu DM, Pădureanu V, Dobrinescu AC, Dobrinescu AG, Mită A, Foarfă MC, Bălă VS, Muşetescu AE, Ionovici N, ForŢofoiu M.

Rom J Morphol Embryol. 2017;58(3):1057-1064.


Association of Quantitative Metastatic Lymph Node Burden With Survival in Hypopharyngeal and Laryngeal Cancer.

Ho AS, Kim S, Tighiouart M, Gudino C, Mita A, Scher KS, Laury A, Prasad R, Shiao SL, Ali N, Patio C, Mallen-St Clair J, Van Eyk JE, Zumsteg ZS.

JAMA Oncol. 2018 Jul 1;4(7):985-989. doi: 10.1001/jamaoncol.2017.3852.


Markerless Knee Joint Position Measurement Using Depth Data during Stair Walking.

Ogawa A, Mita A, Yorozu A, Takahashi M.

Sensors (Basel). 2017 Nov 22;17(11). pii: E2698. doi: 10.3390/s17112698.


Facility Volume and Survival in Nasopharyngeal Carcinoma.

Yoshida EJ, Luu M, David JM, Kim S, Mita A, Scher K, Shiao SL, Tighiouart M, Lee NY, Ho AS, Zumsteg ZS.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):408-417. doi: 10.1016/j.ijrobp.2017.09.038. Epub 2017 Sep 28.


Predictors of survival in head and neck mucosal melanoma.

Schmidt MQ, David J, Yoshida EJ, Scher K, Mita A, Shiao SL, Ho AS, Zumsteg ZS.

Oral Oncol. 2017 Oct;73:36-42. doi: 10.1016/j.oraloncology.2017.08.002. Epub 2017 Aug 10.


Supplemental Content

Loading ...
Support Center